Genflow Biosciences Plc (GB:GENF)
LSE:GENF
Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
2.25 p
-0.02 p(-1.09%)
At close: 4:00 PM EST
2.25 p
-0.02 p(-1.09%)
Day’s Range― - ―
52-Week Range0.55 p - 3.12 p
Previous CloseN/A
Volume13.76K
Average Volume (3M)1.73M
Market Cap
£14.46M
Enterprise Value13.97M
Total Cash (Recent Filing)£279.44K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding535,653,200
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtHaving no financial debt meaningfully lowers refinancing and interest-rate risk for a pre-revenue biotech. This preserves flexibility to time equity or partnership financing, avoids covenants that can constrain R&D, and reduces near-term liquidity pressure across a 2–6 month horizon.
Aging-focused R&D NicheA focused strategy on ageing biology and gene-based approaches targets a large, structural market with rising demand and unmet needs. This scientific specialization can create differentiation, attract partnerships and long-term investor interest if programs advance, sustaining strategy over months to years.
Improving Loss And FCF TrendSequential improvement in net loss and free cash flow suggests early progress toward better cost discipline or project prioritization. While still negative, improving trends reduce immediate financing urgency and indicate management can eke out operational efficiencies over the next few quarters.
Bears Say
Pre-revenue With Operating LossesZero reported revenue and recurring operating losses mean the business lacks internal cash generation and commercial validation. Over the next 2–6 months this maintains high execution risk, limits leverage in partner talks and necessitates external capital to sustain R&D and operations.
Negative Shareholders' EquityAccumulated losses driving equity negative signal weakened balance-sheet resilience and potential solvency concerns. Negative equity can deter lenders and partners, constrain financing options to dilutive equity or expensive instruments, and raise structural risk over the medium term.
Consistent Cash BurnSustained negative operating and free cash flow forces reliance on external funding to continue R&D. Regular fundraising risks dilution, distracts management, and can delay programs if capital markets tighten, making execution and development timelines vulnerable over coming quarters.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 0.55 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £14.46M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 141 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 535,653,200 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---